Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Study With OXN to Evaluate the Patient Preference for Pain Treatment With Respect to Quality of Life After WHO Stap I or Step II Analgesics for Patients With Moderate to Severe Non-malignant Pain

Trial Profile

An Open Study With OXN to Evaluate the Patient Preference for Pain Treatment With Respect to Quality of Life After WHO Stap I or Step II Analgesics for Patients With Moderate to Severe Non-malignant Pain

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naloxone/oxycodone (Primary)
  • Indications Pain
  • Focus Therapeutic Use
  • Acronyms PREFER
  • Sponsors Mundipharma CVA

Most Recent Events

  • 04 Jul 2012 Planned number of patients changed from 180 to 215 as reported by European Clinical Trials Database (EudraCT2008-001026-14).
  • 21 Jul 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health record NCT01167699).
  • 21 Jul 2010 Actual initiation date (Jun 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top